The University of Chicago Header Logo

Connection

Randy Sweis to Humans

Back to Details
This is a "connection" page, showing publications Randy Sweis has written about Humans.
Randy Sweis
Connection Strength
0.575
Humans
  1. A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer. Clin Cancer Res. 2025 Jan 17; 31(2):299-307.
    View in: PubMed
    Score: 0.029
  2. Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial. JAMA Oncol. 2024 11; 10(11):1565-1570.
    View in: PubMed
    Score: 0.028
  3. STING activators in cancer care. Clin Adv Hematol Oncol. 2024 Sep; 22(7):331-333.
    View in: PubMed
    Score: 0.028
  4. The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy. Curr Oncol Rep. 2023 03; 25(3):189-199.
    View in: PubMed
    Score: 0.025
  5. Multi-step screening of neoantigens' HLA- and TCR-interfaces improves prediction of survival. Sci Rep. 2021 05 11; 11(1):9983.
    View in: PubMed
    Score: 0.022
  6. FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer. Front Immunol. 2020; 11:575258.
    View in: PubMed
    Score: 0.022
  7. The Tumor Microenvironment of Bladder Cancer. Adv Exp Med Biol. 2020; 1296:275-290.
    View in: PubMed
    Score: 0.020
  8. Methods to assess anticancer immune responses in orthotopic bladder carcinomas. Methods Enzymol. 2020; 635:127-137.
    View in: PubMed
    Score: 0.020
  9. Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer. JAMA Oncol. 2019 05 01; 5(5):743.
    View in: PubMed
    Score: 0.020
  10. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy. J Immunother Cancer. 2019 03 11; 7(1):66.
    View in: PubMed
    Score: 0.019
  11. Low clinical adoption of tumor genomic profiling: cause for concern? J Med Econ. 2018 Jul; 21(7):721-723.
    View in: PubMed
    Score: 0.018
  12. Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer. 2018 04 04; 6(1):24.
    View in: PubMed
    Score: 0.018
  13. Mechanistic and pharmacologic insights on immune checkpoint inhibitors. Pharmacol Res. 2017 Jun; 120:1-9.
    View in: PubMed
    Score: 0.017
  14. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers. Urol Oncol. 2016 12; 34(12):556-565.
    View in: PubMed
    Score: 0.016
  15. Obviating the Need for Serial Biopsies Through Random Assignment. J Clin Oncol. 2017 01 10; 35(2):260.
    View in: PubMed
    Score: 0.016
  16. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212.
    View in: PubMed
    Score: 0.016
  17. Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res. 2016 07; 4(7):563-8.
    View in: PubMed
    Score: 0.016
  18. Reply to T.A. Yap et al. J Clin Oncol. 2016 07 10; 34(20):2432-3.
    View in: PubMed
    Score: 0.016
  19. Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials. J Clin Oncol. 2016 Feb 01; 34(4):369-74.
    View in: PubMed
    Score: 0.015
  20. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients. Aliment Pharmacol Ther. 2013 Jun; 37(11):1093-102.
    View in: PubMed
    Score: 0.013
  21. Actinomyces-induced inflammatory pseudotumor of the lymph node mimicking scrofula. Ann Intern Med. 2011 Jul 05; 155(1):66-7.
    View in: PubMed
    Score: 0.011
  22. PKCd Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells. Cancer Immunol Res. 2025 Apr 02; 13(4):547-559.
    View in: PubMed
    Score: 0.007
  23. Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2025 Apr 01; 31(7):1233-1242.
    View in: PubMed
    Score: 0.007
  24. High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration. Breast Cancer Res Treat. 2025 Feb; 209(3):563-572.
    View in: PubMed
    Score: 0.007
  25. Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2025 Jan 02; 392(1):45-55.
    View in: PubMed
    Score: 0.007
  26. A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jun 03; 30(11):2384-2392.
    View in: PubMed
    Score: 0.007
  27. Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. Cell Rep. 2024 05 28; 43(5):114141.
    View in: PubMed
    Score: 0.007
  28. Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model. Front Immunol. 2024; 15:1358019.
    View in: PubMed
    Score: 0.007
  29. A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma. Invest New Drugs. 2024 Apr; 42(2):179-184.
    View in: PubMed
    Score: 0.007
  30. NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024. J Natl Compr Canc Netw. 2024 02; 22(1):4-16.
    View in: PubMed
    Score: 0.007
  31. Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 04; 22(2):476-482.e1.
    View in: PubMed
    Score: 0.007
  32. Melanoma and microbiota: Current understanding and future directions. Cancer Cell. 2024 01 08; 42(1):16-34.
    View in: PubMed
    Score: 0.007
  33. Mathematical model predicts tumor control patterns induced by fast and slow cytotoxic T lymphocyte killing mechanisms. Sci Rep. 2023 12 18; 13(1):22541.
    View in: PubMed
    Score: 0.007
  34. A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma. Eur Urol Oncol. 2024 Aug; 7(4):933-943.
    View in: PubMed
    Score: 0.007
  35. Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study. Clin Cancer Res. 2023 01 04; 29(1):110-121.
    View in: PubMed
    Score: 0.006
  36. Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 05 13; 28(10):2020-2029.
    View in: PubMed
    Score: 0.006
  37. Hallmarks of Resistance to Immune-Checkpoint Inhibitors. Cancer Immunol Res. 2022 04 01; 10(4):372-383.
    View in: PubMed
    Score: 0.006
  38. Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2022 02 15; 28(4):677-688.
    View in: PubMed
    Score: 0.006
  39. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol. 2021 07; 22(7):946-958.
    View in: PubMed
    Score: 0.006
  40. Wnt-ß-catenin activation epigenetically reprograms Treg cells in inflammatory bowel disease and dysplastic progression. Nat Immunol. 2021 04; 22(4):471-484.
    View in: PubMed
    Score: 0.006
  41. Germline genetic contribution to the immune landscape of cancer. Immunity. 2021 02 09; 54(2):367-386.e8.
    View in: PubMed
    Score: 0.006
  42. Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomies. Hum Pathol. 2020 12; 106:54-61.
    View in: PubMed
    Score: 0.005
  43. Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. JAMA Oncol. 2019 12 01; 5(12):1790-1798.
    View in: PubMed
    Score: 0.005
  44. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer. 2019 05 22; 7(1):131.
    View in: PubMed
    Score: 0.005
  45. WNT/ß-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clin Cancer Res. 2019 May 15; 25(10):3074-3083.
    View in: PubMed
    Score: 0.005
  46. Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma. Clin Genitourin Cancer. 2019 Feb; 17(1):e12-e18.
    View in: PubMed
    Score: 0.005
  47. T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res. 2018 09; 6(9):990-1000.
    View in: PubMed
    Score: 0.005
  48. Do clinicians know which of their patients have central venous catheters?: a multicenter observational study. Ann Intern Med. 2014 Oct 21; 161(8):562-7.
    View in: PubMed
    Score: 0.004
  49. Tumor endothelial inflammation predicts clinical outcome in diverse human cancers. PLoS One. 2012; 7(10):e46104.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.